En Es
Categories

Industry News


Vircell’s Monotest Responds to New Diagnostic Needs for Testing Patients at Risk of Invasive Aspergillosis

By Labmedica International staff writers
12 Nov 2020

Image: COVID?19 VIRCLIA® IgG Monotest (Photo courtesy of Vircell S.L.)A new monotest using chemiluminescence developed by Vircell S.L. (Granada, Spain) could respond to the new diagnostic needs for testing individual samples immediately of patients at risk of invasive aspergillosis, without the need for batching, cumulating samples or sending out to an external laboratory.

Aspergillus sp. is one of the most ubiquitous of the airborne saprophytic fungi. With the increase in the number of immune-suppressed patients, there has been a dramatic increase in severe and usually fatal invasive aspergillosis or invasive candidiasis, now one of the most common mold infections worldwide. Invasive Aspergillus Infection (IAI) is an important life-threatening infection in immune-compromised patients, especially those with prolonged neutropenia, allogeneic hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT). In immune-competent hosts, IAI is involved in chronic obstructive pulmonary, Large Burned patients, cirrhosis, corticosteroid treatment, most of them located in Intensive Care Units.

Diagnosis of IAI by conventional culture-based methods show clear deficiencies especially in sensitivity and speed: Confirmation with culture occurs in less than 50% of cases due to the frequent negative results of blood cultures and the difficulty of obtaining deep tissue samples or fluids ordinarily sterile. The availability of effective antifungal agents determines the need for rapid and accurate diagnosis. Therefore, it is essential to implement the diagnosis of invasive mycosis with non-culture-based techniques among which biomarkers are already an essential part.

Currently, the most commonly biomarker used in the case of Aspergillus is the Galactomannan. Galactomannan is a useful diagnostic test for the investigation of invasive aspergillosis in patients with a suggestive clinic. It can be done not only in blood but also in CSF, BAL or peritoneal fluid. Its systematic and periodic use is not recommended in non-symptomatic hematological patients who have been receiving antifungal prophylaxis. However, the format currently marketed by a microtiter plate capture ELISA makes it very difficult to use the test with only one or a few samples. The ELISA method is useful when studying a large number of patients at risk of invasive aspergillosis in a systematic way. New formats are now needed to facilitate its use with a single sample. These new systems must be able to quantify the fungal load and be easy to carry out. One model would be the new immunochromatography based on “Lateral Flow”, which is a very simple, but difficult to quantify technique.

Now, the VirClia ASPERGILLUS GALACTOMANNAN AG, a new monotest using chemiluminescence developed by Vircell, could respond to these new diagnostic needs for testing individual samples immediately, without the need for batching, cumulating samples or sending out to an external laboratory. The VirClia ASPERGILLUS GALACTOMANNAN AG has been successfully evaluated internally and externally against a commercially available ELISA reference assay. The VirClia Galactomannan assay showed a 91% correlation with the Platelia Galactomannan (Bio-Rad). As mentioned by the authors in their conclusions, “Both tests showed concordant results in 91% of the cases. Virclia was more convenient for rapid detection of GLM and proved more sensitive for the detection of cases of Invasive Aspergillosis when results were discordant.”



E-mail Print
FaceBook Twitter Google+ Linked in

Vircell S.L.

Vircell is a biotechnology company specialized in the development and production of ready-to-use reagents for the diagnosis of infectious diseases in humans by different techniques – ranging from the traditional Cell Culture or ELISA and IFI Tests to the most innovating developments in the field of Molecular Biology
Gold member
More info

Additional news

02 Dec 2020
Hologic Receives FDA Clearance for Genius AI Detection Technology for Early Breast Cancer Detection
Hologic, Inc. (Marlborough, MA, USA) has received US Food and Drug Administration (FDA) clearance for its Genius AI Detection technology, a new deep learning-based software designed to help radiologists detect subtle potential cancers in breast tomosynthesis images.
Read More
19 Nov 2020
Nova Biomedical Launches New Laboratory Blood Glucose Reference Analyzer
Nova Biomedical (Waltham, MA, USA) has launched Nova Primary, a rapid, accurate, easy to use, blood glucose laboratory analyzer that fills the need for a new glucose reference analyzer to replace the YSI STAT PLUS 2300 Glucose and L-Lactate analyzer from YSI, Inc., (Yellow Springs, OH, USA).
Read More
11 Nov 2020
Streck Launches Rapid, Modular qPCR Instrument with Market-Leading Speed
Streck (La Vista, NE, USA) has launched the Zulu RT, a rapid, modular qPCR instrument capable of performing four independent experiments simultaneously. It can perform a 40-cycle, 6-channel 3-step real-time PCR in less than 20 minutes, making it the fastest qPCR instrument in the world.
Read More
10 Nov 2020
COVID-19 Acceleration and Rising Severity Driving Global Ventilator Market
The global ventilator market was valued at USD 11.4 billion in 2019 and has witnessed a growth surge of up to 172% in 2020 as an exponential rise in respiratory infections due to the coronavirus pandemic has accelerated the demand for ventilators across the world.
Read More
06 Nov 2020
Enzo Biochem Launches Portable Microplate Reader for Use with Its ELISA and Assay Kits
Enzo Biochem (New York, NY, USA) has launched a small portable microplate reader for use with the company’s immunoassays and, ultimately, molecular diagnostics, providing new opportunities in point-of-care medicine.
Read More
28 Oct 2020
Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership
The game-changing partnership between Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany) continues to alter the testing landscape and capabilities of both laboratory and non-laboratory settings for rapidly detecting COVID-19.
Read More
20 Oct 2020
Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually
High-volume laboratories face several challenges, including high instrument failure rate, errors due to several manual steps, low efficiency and long TAT, and heavier workload for the lab staff.
Read More
23 Sep 2020
AI in Medical Imaging to Reach USD 1.5 Billion by 2024
The global market for AI-based clinical applications for use in medical imaging is set to reach almost USD 1.5 billion by 2024 despite a slower-than-expected uptake of these products and the impact of the COVID-19 pandemic.
Read More
16 Sep 2020
MEDICA and COMPAMED 2020 to Take Place Entirely Online From 16-19 November 2020
MEDICA 2020 and COMPAMED 2020, both leading information and communication platforms for the medical technology industry and supplier industry for the medical technology industry, will take place entirely online from 16 to 19 November.
Read More
Copyright © 2000-2020 TradeMed.com. All rights reserved. | Terms And Conditions